

# Examining the efficacy of faecal immunochemical testing (FIT) in patients with Lynch Syndrome

<b>Submission date</b> 09/07/2021	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 13/07/2021	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 26/02/2026	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Lynch Syndrome (LS) is an inherited disorder that results in an increased lifetime risk of several cancers, including colorectal cancer (CRC). It is estimated that nearly 175,000 people in the U.K. have Lynch Syndrome, though fewer than 5% (~8,750) are known.

Given the increased risk of CRC for individuals with LS, colonoscopy (a test to check inside the bowels) is recommended every two years for patients with LS within England, which may begin between the ages of 25 – 35 and last until 75 years of age. Though colonoscopy is presently considered the gold standard for the detection of colonic lesions, the requirement of having up to 25 colonoscopies throughout a LS patient's lifetime is invasive and resource intensive.

For this research study, we are proposing the use of a non-invasive, self-sampling diagnostic device known as the faecal immunochemical testing (FIT) kit for patients with LS. FIT is a CLIA-waived diagnostic device designed to detect trace amounts of faecal haemoglobin (f-Hb) and used to guide clinical referral for lower gastrointestinal investigation, often to colonoscopy. Despite the routine use of FIT in population-based CRC screening programmes within the U.K. and abroad, the role of FIT for patients with LS is unknown.

### Who can participate?

Individuals (men and women) aged 25–75 years who have a diagnosis of Lynch Syndrome.

### What does the study involve?

In this study, we will offer eligible LS patients an OC-Sensor™ FIT kit via mail at baseline, and annually for 3 years thereafter. Patients will also receive additional study materials at baseline, as well as a pre-notification letter just prior to baseline. After the trial has ended, we will continue to passively observe a subset of trial participants (those with preceding negative FIT results), for the observation of interval CRC's. The mechanism for collecting long-term follow up data at 3 years is dependent on future funding, however, and will therefore be decided at a later date.

### What are the possible benefits and risks of participating?

By participating in this study there is a chance that your FIT results may provide your clinician

with additional information which may assist them with your clinical care. You will also be contributing to research that will help improve surveillance for people with Lynch Syndrome in the future. There are no immediate risks in taking part in this research study, and it is unlikely that you will come to any harm while collecting a stool sample as part of the FIT kit sampling. FIT testing is used routinely as part of the National Bowel Cancer Screening Programme and has been deemed safe and effective in this setting. You may, however, be referred for an additional colonoscopy(s). Although this procedure is not considered as part of this research study, there are some risks associated with colonoscopies. Please enquire about any of these risks directly with your consultant.

Where is the study run from?  
King's College London (UK)

When is the study starting and how long is it expected to run for?  
March 2021 to December 2026

Who is funding the study?  
1. MAST Group Ltd (UK)  
2. 40TUDE Curing Colon Cancer (UK)

Who is the main contact?  
Dr Nick Dai  
Dr Kevin Monahan  
Prof. Peter Sasieni  
FITforLynchStudy@kcl.ac.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Nick Dai

**Contact details**  
St Mark's Academic Institute  
London North West University Healthcare NHS Trust  
Northwick Park  
Watford Road  
Harrow  
United Kingdom  
HA1 3UJ  
-  
nick.dai@nhs.net

**Type(s)**  
Scientific

**Contact name**  
Dr Kevin Monahan

### **Contact details**

Family Cancer Clinic & Wolfson Unit for Endoscopy  
London North West University Healthcare NHS Trust  
St Mark's Hospital  
Northwick Park  
Watford Road  
Harrow  
United Kingdom  
HA1 3UJ  
+44 (0)20 8235 4270  
k.monahan@nhs.net

### **Type(s)**

Scientific

### **Contact name**

Prof Peter Sasieni

### **Contact details**

QMUL  
Cancer Research UK Cancer Prevention Trials Unit  
1st Floor Empire House, Queen Mary University of London, Whitechapel, 67-75 New Road  
London  
United Kingdom  
E1 1HH  
+44 (0)20 7188 4484  
p.sasieni@qmul.ac.uk

## **Additional identifiers**

### **Integrated Research Application System (IRAS)**

280583

### **Central Portfolio Management System (CPMS)**

48716

## **Study information**

### **Scientific Title**

Exploring the utility and acceptability of Faecal Immunochemical Testing (FIT) as a novel intervention for the improvement of Colorectal Cancer (CRC) surveillance in individuals with Lynch Syndrome

### **Acronym**

FIT for Lynch Syndrome

### **Study objectives**

Based upon preliminary data which came from a preceding emergency clinical service evaluation examining the utility of FIT in patients with Lynch Syndrome throughout the COVID-19 pandemic, we believe that a structured programme and longitudinal research with annual FIT

alongside biannual colonoscopy in this patient cohort will enable a robust dataset to examine the efficacy of FIT as an additive, non-invasive diagnostic modality for the purposes of surveillance in patients with Lynch Syndrome.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 25/03/2021, Yorkshire & The Humber – Bradford Leeds Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)2071048083; bradfordleeds.rec@hra.nhs.uk), ref: 21/YH/0066

### **Study design**

Observational cohort study

### **Primary study design**

Observational

### **Study type(s)**

Screening

### **Health condition(s) or problem(s) studied**

Lynch Syndrome (hereditary non-polyposis colorectal cancer)

### **Interventions**

A baseline mailing will be sent to eligible participants within 30 days of their next standard of care colonoscopy to include the following study materials and items:

1. A study invitation letter
2. A FIT kit (OC-Sensor brand) enclosed within a biospecimen sample bag
3. Consent form
4. FIT instruction sheet (to have pictorial and written instructions for collection)
5. A baseline questionnaire
6. A patient information sheet
7. Return envelope w/ prepaid postage

Eligible patients may read about the study in greater detail within the study invitation letter and the patient information leaflet. Interested patients will then be asked to provide a small faecal sample within the provided FIT kit and per the enclosed FIT instruction sheet. Additionally, they will be asked to complete the consent form and baseline questionnaire (which will assess attitudes of acceptability and preferences for this novel intervention, as well as current medications), all of which will be returned to the NHS Bowel Cancer Screening Programme Southern Hub (referred to as the "Southern Hub" herein), in Guildford, Surrey via the provided return envelope with prepaid postage.

FIT (self-sampling) kits will be posted to enrolled patients annually for 3 years after baseline (Years 1-3) and will include the FIT kit for sample collection, the FIT instruction sheet, a post-baseline letter, and a return envelope with prepaid postage for return to the Southern Hub.

At intervening years between patient's routine (biennial) colonoscopy (years 1 & 3), FIT will be used to inform colonoscopy triage for patients whose result exceeds an upper threshold of 6 micrograms of haemoglobin per gram of faeces. For patients whose FIT result exceeds the pre-

defined upper threshold at those intervening years (whom we expect to be a small minority), results will be disclosed via their physician (Co-I) and they will be advised to proceed with a colonoscopy which shall be triaged via the two-week wait (2WW) pathway.

A subset of FIT-negative patients will be passively followed-up 3 years after the trial ends for the observation of interval CRC's.

To address the primary aim of the study, we will compare results from FIT and the respective pathology and/or histology reports from endoscopy following each colonoscopy from baseline through the subsequent 3 years (4 years total).

## **Intervention Type**

Other

## **Primary outcome(s)**

Confirmation of no visible CRC at time of colonoscopy and subsequent negative pathology report for patients who had preceding negative FIT results. The absence of colorectal cancer is measured by colonoscopy for participants with preceding negative FIT results (<6 micrograms of haemoglobin / g of faeces) at Baseline and Year 2

## **Key secondary outcome(s)**

1. The overall acceptability of this novel intervention (FIT) by this patient population (Lynch Syndrome) will be measured through the use of a participant questionnaire which will be distributed at baseline
2. Confirmation of colorectal neoplasia (CN) at time of colonoscopy, and subsequent confirmation via pathology report for patients who had preceding positive FIT results over the 3-year interventional follow-up period
3. Gut microbiota measured using 16S next-generation sequencing on residual DNA from archived FIT samples at a single time point
4. Colorectal cancer (CRC) diagnoses from patient records in a subset of patients who had negative FIT results at Baseline and Years 1-3 to record for potential interval cancers through Baseline, Years 1-3, and passive follow-up years 4-6
5. Advanced colorectal neoplasia (ACN) at time of colonoscopy, and subsequent confirmation of malignancy on pathology report using patient records over the 5 year follow up period

## **Completion date**

31/12/2026

## **Eligibility**

### **Key inclusion criteria**

1. Individuals (men and women) who have a diagnosis of Lynch Syndrome (as defined by a confirmed mutation in any of the mismatch repair genes (MLH1, MSH2, MSH6, PMS2 or EPCAM),
2. Between the age of 25 - 75 years
3. Have a scheduled standard of care (SOC) routine colonoscopy appointment within the 12 months at start of study recruitment

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

25 years

**Upper age limit**

75 years

**Sex**

All

**Total final enrolment**

421

**Key exclusion criteria**

1. Individuals who have not had genetic testing and therefore are not known to have Lynch Syndrome
2. Individuals who have previously undergone a subtotal or total colectomy
3. Individuals unable to provide informed consent

**Date of first enrolment**

06/09/2021

**Date of final enrolment**

31/12/2023

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**St Mark's Hospital**

Watford Road

Harrow

England

HA1 3UJ

**Study participating centre**

**Guy's Hospital**

Guy's & St Thomas' NHS Foundation Trust

Great Maze Pond

London  
England  
SE1 9RT

**Study participating centre**

**Newcastle Hospital**

Newcastle Upon Tyne Hospital Trust  
High Heaton  
Newcastle  
England  
NE7 7DN

**Study participating centre**

**St George's Hospital**

Blackshaw Road  
London  
England  
SW17 0QT

**Study participating centre**

**The Royal Marsden Hospital**

Fulham Road  
Chelsea  
London  
England  
SW3 6JJ

**Study participating centre**

**Central Manchester University Hospitals NHS Foundation Trust**

Cobbett House  
Oxford Road  
Manchester  
England  
M13 9WL

**Study participating centre**

**Birmingham Women's and Children's NHS Foundation Trust**

Steelhouse Lane  
Birmingham  
England  
B4 6NH

**Study participating centre**  
**John Radcliffe Hospital**  
Headley Way  
Oxford  
England  
OX3 9DU

## Sponsor information

**Organisation**  
London North West Healthcare NHS Trust

**ROR**  
<https://ror.org/04cntmc13>

## Funder(s)

**Funder type**  
Industry

**Funder Name**  
MAST GROUP LIMITED

**Funder Name**  
40TUDE CURING COLON CANCER

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

### IPD sharing plan summary

Published as a supplement to the results publication

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

<a href="#">Results article</a>	05/09/2023	06/09/2023	Yes	No
<a href="#">Protocol article</a>	07/11/2022	08/11/2022	Yes	No
<a href="#">HRA research summary</a>		28/06/2023	No	No